{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T20:28:58Z","timestamp":1783715338018,"version":"3.55.0"},"reference-count":29,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2021,8]]},"abstract":"Abstract<\/jats:title>\n \n Study Objectives<\/jats:title>\n \n The most commonly prescribed antibiotics for patients with hospital\u2010acquired bacterial pneumonia (HABP) and ventilator\u2010associated bacterial pneumonia (VABP) due to\n Pseudomonas aeruginosa<\/jats:italic>\n are the conventional anti\u2010pseudomonal \u03b2\u2010lactams (APBLs) (ie, ceftazidime, cefepime, meropenem, or piperacillin\u2010tazobactam). Similar resistance mechanisms in\n P<\/jats:italic>\n .\u00a0\n aeruginosa<\/jats:italic>\n affect the APBLs, and it is unclear if resistance to one APBL can affect the effectiveness of other APBLs. This exploratory, hypothesis\u2010generating analysis evaluates the impact of APBL resistance among patients in the intensive care unit (ICU) with\n P<\/jats:italic>\n .\u00a0\n aeruginosa<\/jats:italic>\n HABP\/VABP who initially receive a microbiologically active APBL.\n <\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n A retrospective cohort [GJ1] [LT2] study.<\/jats:p>\n <\/jats:sec>\n \n Setting<\/jats:title>\n Kaiser Permanente Southern California members (01\/01\/2011\u201012\/31\/2017).<\/jats:p>\n <\/jats:sec>\n \n Patients<\/jats:title>\n \n The study included adult patients admitted to the ICU with a monomicrobial\n P<\/jats:italic>\n .\n aeruginosa<\/jats:italic>\n HABP\/VABP who received a microbiologically active APBL within 2 days of index\n P<\/jats:italic>\n .\n aeruginosa<\/jats:italic>\n respiratory culture.\n <\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n \n Patients were stratified by presence of resistance to APBL on index\n P<\/jats:italic>\n .\n aeruginosa<\/jats:italic>\n (0 vs. \u22651 resistant APBL).\n <\/jats:p>\n <\/jats:sec>\n \n Measurements<\/jats:title>\n Primary outcomes were 30\u2010day mortality and discharge to home.<\/jats:p>\n <\/jats:sec>\n \n Main Results<\/jats:title>\n \n Overall, 553 patients were included. Thirty\u2010day mortality was 28%, and 32% of patients were discharged home. Eighty\u2010eight patients (16%) had a\n P<\/jats:italic>\n .\u00a0\n aeruginosa<\/jats:italic>\n HABP\/VABP that was resistant to \u22651 APBL (other than active empiric treatment). Relative to patients with no APBL resistance, patients with resistance to \u22651 APBL had a higher 30\u2010day mortality (adjusted odds ratio (aOR) [95% confidence interval (CI)]: 1.65 [1.02\u20132.66]) and were less likely to be discharged home (adjusted hazard ratio (aHR) [95% CI]: 0.50 [0.29\u20130.85]).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n Further study is needed, but this exploratory analysis suggests that the full APBL susceptibility profile should be considered when selecting therapy for patients with\n P<\/jats:italic>\n .\u00a0\n aeruginosa<\/jats:italic>\n HABP\/VABP.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/phar.2600","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T13:37:37Z","timestamp":1623073057000},"page":"658-667","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Outcomes of adult patients in the intensive care unit with\n Pseudomonas<\/i>\n aeruginosa<\/i>\n pneumonia who received an active anti\u2010pseudomonal \u03b2\u2010lactam: Does \u201cS\u201d equal success in the presence of resistance to other anti\u2010pseudomonal \u03b2\u2010lactams?"],"prefix":"10.1002","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4730-0655","authenticated-orcid":false,"given":"Thomas P.","family":"Lodise","sequence":"first","affiliation":[{"name":"Abany College of Pharmacy Health Sciences Albany New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Puzniak","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. Kenilworth New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lie H.","family":"Chen","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Southern California Department of Research & Evaluation Pasadena California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Tian","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Southern California Department of Research & Evaluation Pasadena California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Wei","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Southern California Department of Research & Evaluation Pasadena California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa M.","family":"Im","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Southern California Department of Research & Evaluation Pasadena California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Y.","family":"Tartof","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Southern California Department of Research & Evaluation Pasadena California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,7,5]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"2542","article-title":"Emerging infections program healthcare\u2010associated I, antimicrobial use prevalence survey T. Survey of health care\u2010associated infections","volume":"26","author":"Magill SS","year":"2014","journal-title":"N Engl J Med"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2016.174"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw353"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky027"},{"key":"e_1_2_6_6_1","first-page":"78","article-title":"Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: guidelines by the Spanish Society of Chemotherapy","volume":"1","author":"Mensa J","year":"2018","journal-title":"Rev Esp Quimioter"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212527"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1086\/338782"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2017.00039"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00040-09"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.7812\/TPP\/12-031"},{"key":"e_1_2_6_12_1","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2019"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e3182881c8e"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy343"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00851-06"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.3927"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000004000"},{"key":"e_1_2_6_18_1","unstructured":"https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/hospital\u2010acquired\u2010bacterial\u2010pneumonia\u2010and\u2010ventilator\u2010associated\u2010bacterial\u2010pneumonia\u2010developing\u2010drugs"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2014.02.013"},{"key":"e_1_2_6_20_1","unstructured":"Antibacterial Susceptibility Test Interpretive Criteria.https:\/\/www.fda.gov\/drugs\/development\u2010resources\/antibacterial\u2010susceptibility\u2010test\u2010interpretive\u2010criteria"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00747-09"},{"key":"e_1_2_6_22_1","doi-asserted-by":"crossref","first-page":"e00433\u201018","DOI":"10.1128\/AAC.00433-18","article-title":"The inoculum effect in the era of multidrug resistance: minor differences in inoculum have dramatic effect on MIC determination","volume":"8","author":"Smith KP","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-004-2171-2"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01330-10"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e31806518ac"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1086\/529190"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00338-07"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000000897"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000000862"},{"key":"e_1_2_6_30_1","doi-asserted-by":"crossref","first-page":"380","DOI":"10.7326\/M13-1419","article-title":"Variation in diagnostic coding of patients with pneumonia and its association with hospital risk\u2010standardized mortality rates: a cross\u2010sectional analysis","volume":"6","author":"Rothberg MB","year":"2014","journal-title":"Ann Intern Med"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2600","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.2600","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2600","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:07:38Z","timestamp":1761066458000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,5]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1002\/phar.2600"],"URL":"https:\/\/doi.org\/10.1002\/phar.2600","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,5]]},"assertion":[{"value":"2021-01-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}